Table 1 Baseline a characteristics of patients included in analyses of rapid progression, according to availability of data
|  |  | Patients with eGFR data available | ≥4 years follow-up | ≥3 years follow-up | ||||
|---|---|---|---|---|---|---|---|---|
|  |  |  | Unrestrictedf | ≥3 eGFR per year | ≥2 eGFR per year | Unrestricted* | ≥3 eGFR per year | ≥2 eGFR per year |
Eligible patients | Number (%) | 22603 (100) | 13061 (57.8) | 3655 (16.2) | 8298 (36.7) | 16165 (71.5) | 6375 (28.2) | 12283 (54.3) |
Average eGFR | Median (IQR) | 109 (99–123) | 108 (99–122) | 107 (98–121) | 108 (99–121) | 109 (99–122) | 108 (99–122) | 108 (99–122) |
eGFR >120 ml/min | Number (%) | 6613 (29.3) | 3616 (27.7) | 943 (26) | 225 (27) | 4562 (28.1) | 1723 (27) | 3412 (28) |
Gender | Male | 16438 (72.7) | 9335 (71.5) | 2622 (71.7) | 5999 (72.3) | 11613 (71.8) | 4617 (72.4) | 8906 (72.5) |
Race | White | 10573 (46.8) | 6343 (48.6) | 1631 (44.6) | 3835 (46.2) | 7469 (46.2) | 2584 (40.5) | 5454 (44.4) |
Black | 1806 (8.0) | 1141 (8.7) | 354 (9.7) | 720 (8.7) | 1346 (8.3) | 581 (9.1) | 1023 (8.3) | |
Other | 510 (2.3) | 306 (2.3) | 103 (2.8) | 197 (2.4) | 385 (2.4) | 155 (2.4) | 294 (2.4) | |
Unknown | 9714 (43.0) | 5271 (40.4) | 1567 (42.9) | 3546 (42.7) | 6965 (43.1) | 3055 (47.9) | 5512 (44.9) | |
Age group | >50 years | 2238 (9.9) | 1280 (9.8) | 410 (11.2) | 868 (10.5) | 1641 (10.2) | 702 (11.0) | 1309 (10.7) |
Hypertensionb | Yes | 2519 (11.1) | 1526 (11.7) | 494 (13.5) | 1030 (12.4) | 1865 (11.5) | 784 (12.3) | 1458 (11.9) |
Diabetesc | Yes | 659 (2.9) | 428 (3.3) | 145 (4.0) | 290 (3.5) | 517 (3.2) | 237 (3.7) | 413 (3.4) |
Mode of HIV acquisition | Homosexual | 10006 (44.3) | 5642 (43.2) | 1611 (44.1) | 3710 (44.7) | 7028 (43.5) | 2876 (45.1) | 5487 (44.7) |
IDU | 3058 (13.5) | 1783 (13.7) | 450 (12.3) | 1019 (12.3) | 2196 (13.6) | 740 (11.6) | 1540 (12.5) | |
Heterosexual | 8095 (35.8) | 4865 (37.3) | 1385 (37.9) | 3081 (37.1) | 5952 (36.8) | 2359 (37.0) | 4499 (36.6) | |
Other | 1444 (6.4) | 771 (5.9) | 209 (5.7) | 488 (5.9) | 989 (6.1) | 400 (6.3) | 757 (6.2) | |
BMI at study entry (kg/m2) | <18 | 633 (2.8) | 345 (2.6) | 91 (2.5) | 216 (2.6) | 440 (2.7) | 169 (2.7) | 330 (2.7) |
≥18, <26 | 15865 (70.2) | 9310 (71.3) | 2542 (69.6) | 5877 (70.8) | 11473 (71.0) | 4466 (70.1) | 8717 (71.0) | |
≥26, <30 | 3716 (16.4) | 2231 (17.1) | 677 (18.5) | 1466 (17.7) | 2727 (16.9) | 1106 (17.4) | 2088 (17.0) | |
≥30 | 1423 (6.3) | 845 (6.5) | 238 (6.5) | 536 (6.5) | 1037 (6.4) | 398 (6.2) | 774 (6.3) | |
Unknown | 966 (4.3) | 330 (2.5) | 107 (2.9) | 203 (2.5) | 488 (3.0) | 236 (3.7) | 374 (3.0) | |
Hepatitis Cd positive | Yes | 2765 (12.2) | 1605 (12.3) | 400 (10.9) | 910 (11.0) | 1958 (12.1) | 653 (10.2) | 1346 (10.6) |
Hepatitis Be positive | Yes | 2773 (12.3) | 1551 (12.4) | 450 (12.3) | 1001 (12.1) | 1971 (12.2) | 816 (12.8) | 1501 (12.2) |
Smoking status | Current | 9544 (42.2) | 5554 (42.5) | 1467 (40.1) | 3445 (41.5) | 6930 (42.9) | 2571 (40.3) | 5198 (42.3) |
Previous | 3930 (17.4) | 2426 (18.6) | 681 (18.6) | 1557 (18.8) | 2923 (18.1) | 1193 (18.7) | 2248 (18.3) | |
Never | 5824 (25.8) | 3599 (27.6) | 1086 (29.7) | 2332 (28.1) | 4314 (26.7) | 1726 (27.1) | 3299 (26.9) | |
Unknown | 3305 (14.6) | 1482 (11.4) | 421 (11.5) | 964 (11.6) | 1998 (12.4) | 885 (13.9) | 1538 (12.5) | |
Current CD4 count (cells/mm3) | <200 | 2823 (12.5) | 1435 (11.0) | 482 (13.2) | 940 (11.3) | 1831 (11.3) | 833 (13.1) | 1424 (11.6) |
200-349 | 4912 (21.7) | 2797 (21.4) | 826 (22.6) | 1807 (21.8) | 3427 (21.2) | 1444 (22.7) | 2641 (21.5) | |
350-499 | 5565 (24.6) | 3294 (25.2) | 963 (26.4) | 2109 (25.4) | 4049 (25.1) | 1632 (25.6) | 3078 (25.1) | |
≥500 | 9145 (40.5) | 5492 (42.1) | 1371 (37.5) | 3417 (41.2) | 6779 (41.9) | 2432 (38.2) | 5079 (41.4) | |
| Â | Missing | 158 (0.7) | 43 (0.3) | 13 (0.4) | 25 (0.3) | 79 (0.5) | 34 (0.5) | 61 (0.5) |